Glubia Tablet 100 mg (Sitagliptin Phosphate Hydrate)
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Hanol BioPharma Co., Ltd.
MFDS item code 201502380 · Approved 2015.04.20
This product's status changed to Expired on 2025.04.20. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication helps control blood sugar levels in patients with type 2 diabetes and is used in conjunction with dietary and exercise therapies. It can be administered alone, but in cases where there is no previous experience with diabetes medications and blood sugar control is difficult with monotherapy, it may be combined with metformin. Additionally, when blood sugar control is insufficient with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is administered in combination. Even when multiple medications are used together, if sufficient blood sugar control is challenging, this medication is added to enhance therapeutic efficacy. Thus, this medication is used to improve blood sugar control in various treatment situations.
This medicine is administered at a dose of 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. It may be taken with or without food. When administered in combination with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, renal function should be assessed before treatment with this medicine and periodically thereafter. 1. No dose adjustment is required in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may rarely cause severe allergic reactions after administration; if symptoms such as skin rash or difficulty breathing occur, stop taking the medication immediately and consult a physician. Symptoms of pancreatitis, such as abdominal pain, vomiting, and loss of appetite may occur; if these symptoms arise, stop taking this medication immediately and visit a hospital. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with known allergies to this medication or its ingredients should avoid using it. Patients with reduced kidney function need to adjust the dosage of this medication, and routine kidney function tests should be conducted before and during treatment. The risk of hypoglycemia may increase when taken together with other antidiabetic agents, particularly insulin or sulfonylureas, so careful monitoring of blood sugar changes is required. This medication may cause side effects such as headache, upper respiratory infection, nasopharyngitis, diarrhea, etc.; if these symptoms are severe or persistent, consult a physician. If severe joint pain or skin blisters occur, inform a physician immediately, and if necessary, discontinue the medication. The use of this medication is not recommended for pregnant or breastfeeding women, and its safety in children under 18 has not been established. Elderly patients may require dose adjustment and kidney function tests due to the possibility of reduced kidney function. In case of overdose, go to a hospital promptly for appropriate treatment, and if necessary, blood dialysis may be possible for drug removal. The cardiovascular safety of this medication is confirmed; however, patients with pre-existing cardiovascular disease should take it according to a physician's guidance. There may be interactions with other medications, so be sure to inform your doctor or pharmacist of any medications you are currently taking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air from entering and should be kept at room temperature between 1 to 30 degrees Celsius. Storing it this way helps maintain the drug's efficacy.
Beige round, biconvex, film-coated tablet
28 tablets/box [14 tablets/PTP*2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Hanol BioPharma Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.